217 related articles for article (PubMed ID: 34593218)
1. [Molecular genotyping in refractory thyroid cancers in 2021: When, how and why? A review from the TUTHYREF network].
de la Fouchardière C; Wassermann J; Calcagno F; Bardet S; Al Ghuzlan A; Borget I; Borson Chazot F; Do Cao C; Buffet C; Zerdoud S; Decaussin-Petrucci M; Godbert Y; Leboulleux S
Bull Cancer; 2021 Nov; 108(11):1044-1056. PubMed ID: 34593218
[TBL] [Abstract][Full Text] [Related]
2. Molecular Pathology of Anaplastic Thyroid Carcinomas: A Retrospective Study of 144 Cases.
Bonhomme B; Godbert Y; Perot G; Al Ghuzlan A; Bardet S; Belleannée G; Crinière L; Do Cao C; Fouilloux G; Guyetant S; Kelly A; Leboulleux S; Buffet C; Leteurtre E; Michels JJ; Tissier F; Toubert ME; Wassef M; Pinard C; Hostein I; Soubeyran I
Thyroid; 2017 May; 27(5):682-692. PubMed ID: 28351340
[TBL] [Abstract][Full Text] [Related]
3. Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies.
Molinaro E; Romei C; Biagini A; Sabini E; Agate L; Mazzeo S; Materazzi G; Sellari-Franceschini S; Ribechini A; Torregrossa L; Basolo F; Vitti P; Elisei R
Nat Rev Endocrinol; 2017 Nov; 13(11):644-660. PubMed ID: 28707679
[TBL] [Abstract][Full Text] [Related]
4. From nodule to differentiated thyroid carcinoma: contributions of molecular analysis in 2012.
Albarel F; Conte-Devolx B; Oliver C
Ann Endocrinol (Paris); 2012 Jun; 73(3):155-64. PubMed ID: 22503804
[TBL] [Abstract][Full Text] [Related]
5. Progress in Treating Advanced Thyroid Cancers in the Era of Targeted Therapy.
Lubitz CC; Sadow PM; Daniels GH; Wirth LJ
Thyroid; 2021 Oct; 31(10):1451-1462. PubMed ID: 33860688
[No Abstract] [Full Text] [Related]
6. NTRK fusion oncogenes in pediatric papillary thyroid carcinoma in northeast United States.
Prasad ML; Vyas M; Horne MJ; Virk RK; Morotti R; Liu Z; Tallini G; Nikiforova MN; Christison-Lagay ER; Udelsman R; Dinauer CA; Nikiforov YE
Cancer; 2016 Apr; 122(7):1097-107. PubMed ID: 26784937
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological features and immunohistochemical utility of NTRK-, ALK-, and ROS1-rearranged papillary thyroid carcinomas and anaplastic thyroid carcinomas.
Nozaki Y; Yamamoto H; Iwasaki T; Sato M; Jiromaru R; Hongo T; Yasumatsu R; Oda Y
Hum Pathol; 2020 Dec; 106():82-92. PubMed ID: 32980422
[TBL] [Abstract][Full Text] [Related]
8. Pediatric, Adolescent, and Young Adult Thyroid Carcinoma Harbors Frequent and Diverse Targetable Genomic Alterations, Including Kinase Fusions.
Vanden Borre P; Schrock AB; Anderson PM; Morris JC; Heilmann AM; Holmes O; Wang K; Johnson A; Waguespack SG; Ou SI; Khan S; Fung KM; Stephens PJ; Erlich RL; Miller VA; Ross JS; Ali SM
Oncologist; 2017 Mar; 22(3):255-263. PubMed ID: 28209747
[TBL] [Abstract][Full Text] [Related]
9. Anaplastic Thyroid Carcinoma: Current Issues in Genomics and Therapeutics.
Abe I; Lam AK
Curr Oncol Rep; 2021 Feb; 23(3):31. PubMed ID: 33582932
[TBL] [Abstract][Full Text] [Related]
10. Targeted therapy: a new hope for thyroid carcinomas.
Perri F; Pezzullo L; Chiofalo MG; Lastoria S; Di Gennaro F; Scarpati GD; Caponigro F
Crit Rev Oncol Hematol; 2015 Apr; 94(1):55-63. PubMed ID: 25465739
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathological characteristics of thyroid cancer in the federal state of Salzburg.
Rendl G; Rodrigues M; Schweighofer-Zwink G; Hutter J; Hittmair A; Zellinger B; Hauser-Kronberger C; Pirich C
Wien Klin Wochenschr; 2017 Aug; 129(15-16):540-544. PubMed ID: 28493027
[TBL] [Abstract][Full Text] [Related]
12.
Pekova B; Sykorova V; Dvorakova S; Vaclavikova E; Moravcova J; Katra R; Astl J; Vlcek P; Kodetova D; Vcelak J; Bendlova B
Thyroid; 2020 Dec; 30(12):1771-1780. PubMed ID: 32495721
[No Abstract] [Full Text] [Related]
13. Kinase gene fusions: roles and therapeutic value in progressive and refractory papillary thyroid cancer.
Liu M; Chen P; Hu HY; Ou-Yang DJ; Khushbu RA; Tan HL; Huang P; Chang S
J Cancer Res Clin Oncol; 2021 Feb; 147(2):323-337. PubMed ID: 33387037
[TBL] [Abstract][Full Text] [Related]
14. Recent advances in anaplastic thyroid cancer management.
Hamidi S; Maniakas A
Curr Opin Endocrinol Diabetes Obes; 2023 Oct; 30(5):259-264. PubMed ID: 37410453
[TBL] [Abstract][Full Text] [Related]
15. [Molecular diagnostics enable targeted therapies for anaplastic and poorly differentiated thyroid cancer].
Altena R; Nilsson M; Bergman V; Dahlberg J; Christofer Juhlin C; Zedenius J
Lakartidningen; 2024 Feb; 121():. PubMed ID: 38712675
[TBL] [Abstract][Full Text] [Related]
16. Evolving molecularly targeted therapies for advanced-stage thyroid cancers.
Bible KC; Ryder M
Nat Rev Clin Oncol; 2016 Jul; 13(7):403-16. PubMed ID: 26925962
[TBL] [Abstract][Full Text] [Related]
17. Management of hereditary medullary thyroid carcinoma.
Pappa T; Alevizaki M
Endocrine; 2016 Jul; 53(1):7-17. PubMed ID: 26839093
[TBL] [Abstract][Full Text] [Related]
18. Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers.
Landa I; Ibrahimpasic T; Boucai L; Sinha R; Knauf JA; Shah RH; Dogan S; Ricarte-Filho JC; Krishnamoorthy GP; Xu B; Schultz N; Berger MF; Sander C; Taylor BS; Ghossein R; Ganly I; Fagin JA
J Clin Invest; 2016 Mar; 126(3):1052-66. PubMed ID: 26878173
[TBL] [Abstract][Full Text] [Related]
19. Medical management of metastatic medullary thyroid cancer.
Maxwell JE; Sherman SK; O'Dorisio TM; Howe JR
Cancer; 2014 Nov; 120(21):3287-301. PubMed ID: 24942936
[TBL] [Abstract][Full Text] [Related]
20. Molecular Pathology of Poorly Differentiated and Anaplastic Thyroid Cancer: What Do Pathologists Need to Know?
Volante M; Lam AK; Papotti M; Tallini G
Endocr Pathol; 2021 Mar; 32(1):63-76. PubMed ID: 33543394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
